Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MRA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    99 result(s) found for: MRA. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2007-006014-41 Sponsor Protocol Number: Vasovist MA-01 Start Date*: 2008-04-14
    Sponsor Name:University Heidelberg, University Hospital Mannheim
    Full Title: Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Arte...
    Medical condition: Patients suffering from PAOD stage III or stage IV (confirmed by ECCM MRA, CTA, non-selective DSA, DUS) and have an indication for the evaluation of the entire lower leg axis down to the feet (comm...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002939 Aortoiliac occlusive disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000953-46 Sponsor Protocol Number: SOV301 Start Date*: 2004-10-13
    Sponsor Name:Amersham plc
    Full Title: A Multicentre, Phase 3, Open-Label, Controlled Study Evaluating the Efficacy and Safety of 0.1 mmol/kg Omniscan (Gadodiamide Injection) in Magnetic Resonance Angiography (MRA) of the Renal Arteries
    Medical condition: Renal artery stenosis (RAS) is implicated as the underlying cause in 1% to 5% of patients with hypertension and 5% to 15% of patients with end-stage renal disease entering dialysis programs each ye...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010968-42 Sponsor Protocol Number: DGD-44-045 Start Date*: 2009-07-07
    Sponsor Name:GUERBET
    Full Title: Efficacy evaluation of DOTAREM®-enhanced MRA compared to GADOVIST®–enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases
    Medical condition: Patient suffering from abdominal or lower limb arterial diseases
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062585 Peripheral arterial occlusive disease LLT
    9.1 10062585 Peripheral arterial occlusive disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000994-69 Sponsor Protocol Number: SOV302 Start Date*: 2004-11-11
    Sponsor Name:Amersham Buchler GmbH & Co KG an affiliate of GE Healthcare Bio-Sciences
    Full Title: A multicentre, phase 3, open label study to assess the efficacy and safety of 0.1 mmol/kg Omniscan™ (gadodiamide injection) for Magnetic Resonance Angiography (MRA) of the aorto-iliac arteries
    Medical condition: Suspected or proven chronic PAOD predominantly located in the aorto-iliac region of Fontaine Stages IIb to IV (ie, Rutherford Stages I3-III), or presents with an ankle brachial pressure index of <0...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10062585 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002547-66 Sponsor Protocol Number: 308861 Start Date*: 2005-11-28
    Sponsor Name:Schering AG
    Full Title: Intra-individual open-label multicenter comparison study of magnetic resonance angiography (MRA) with the blood pool contrast agent Vasovist® and a conventional extracellular contrast agent with in...
    Medical condition: Patients who have aortoiliac disease Fontaine-stage IIb – IV and an indication for the evaluation of the infrarenal aorta and the peripheral run-off arteries (i.e. from infrarenal aorta to calves).
    Disease: Version SOC Term Classification Code Term Level
    7.1 10002939 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004325-25 Sponsor Protocol Number: MS325-19 Start Date*: 2007-01-04
    Sponsor Name:Administration management, Ludwig-Maximilians-University of Munich
    Full Title: Comprehensive whole-body 3T MRA of Patients with Low or Moderate Clinical Probability for Pulmonary Embolism using an Intravascular MR Contrast Agent Vasovist®
    Medical condition: Patients with low or moderate clinical probability for pulmonary embolism and positive or negative CTA for pulmonary embolism after CT and sonographic examination for deep venous thrombosis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005176-35 Sponsor Protocol Number: ESR-19-20262 Start Date*: 2021-01-14
    Sponsor Name:Sahlgrenska University Hospital
    Full Title: OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure (OPRA-HF)
    Medical condition: Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002423-13 Sponsor Protocol Number: WA18695 Start Date*: 2005-09-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in WA17822
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) SK (Completed) IT (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-000175-33 Sponsor Protocol Number: D9484C00001 Start Date*: 2018-06-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy with Sodium Zirconium ...
    Medical condition: Heart Failure; Hyperkalaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002078-71 Sponsor Protocol Number: 16758 Start Date*: 2010-06-02
    Sponsor Name:Wilhelmina Children's Hospital/UMC Utrecht
    Full Title: Reductie van Hersenschade na “Perinatal Arterial Stroke”of PAS met recombinant humaan Erythropoietine (rhEPO): Een “Proof of Concept” en “Safety” studie
    Medical condition: treatment of perinatal stroke.
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-005210-37 Sponsor Protocol Number: WA18063 Start Date*: 2005-04-26
    Sponsor Name:F. Hoffmann La-Roche AG
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMAR...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FI (Completed) CZ (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2018-003588-69 Sponsor Protocol Number: W2018.034 Start Date*: 2019-03-07
    Sponsor Name:Leiden University Medical Center
    Full Title: The ENDURRANCE-1 Study. Exploring durable remission with rituximab in ANCA associated vasculitis
    Medical condition: ANCA associated vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002909-23 Sponsor Protocol Number: WA18696 Start Date*: 2005-09-21
    Sponsor Name:F Hoffmann La-Roche AG
    Full Title: Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies. Estudio de extensión, a largo plazo, de la seguridad durante el tra...
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) SE (Completed) NO (Completed) LT (Completed) CZ (Completed) GB (Completed) DK (Completed) FI (Completed) SI (Completed) IT (Completed) IS (Completed) PT (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2004-003741-40 Sponsor Protocol Number: WA17822 Start Date*: 2004-11-26
    Sponsor Name:F. Hoffmann La-Roche AG
    Full Title: A randomized, double-blind, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with methotrexate, in patients with moder...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) SK (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023001-36 Sponsor Protocol Number: BAY86-4875/14607 Start Date*: 2011-04-26
    Sponsor Name:Bayer Health Care AG
    Full Title: Multicenter, open-label study to evaluate the safety and efficacy (by blinded reading) of contrast-enhanced magnetic resonance angiography (MRA) after a single intravenous injection of 0.1 mmol/k...
    Medical condition: Subjects with known or suspected vascular disease of the supra-aortic vessels
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10007687 Carotid artery stenosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SE (Completed) FR (Completed) IT (Completed) PL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001138-33 Sponsor Protocol Number: WA17824 Start Date*: 2005-07-14
    Sponsor Name:F. Hoffmann La-Roche AG
    Full Title: A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of MRA monotherapy, versus methotrexate (MTX) monotherapy, in patients with active rheumatoid arthritis.
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) NO (Completed) SI (Completed) DK (Completed) PT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000929-59 Sponsor Protocol Number: MultiH/BRA/708 Start Date*: Information not available in EudraCT
    Sponsor Name:Bracco ALTANA Pharma GmbH
    Full Title: INTRAINDIVIDUAL CROSS-OVER STUDY TO COMPARE MULTIHANCE® AND MAGNEVIST® AT A DOSE OF 0.1 MMOL/KGBW IN CERVICO-CEREBRAL MR ANGIOGRAPHY AND CEREBRAL MR PERFUSION IMAGING AT 3 TESLA IN PATIENTS WITH CA...
    Medical condition: Carotid artery stenosis and scheduled for MRA, for MR perfusion examination and for an elective stent treatment
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007687 Carotid artery stenosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011002-42 Sponsor Protocol Number: DGD-44-052 Start Date*: 2009-05-29
    Sponsor Name:GUERBET
    Full Title: Intra-individual efficacy evaluation of DOTAREM®-enhanced MRA compared to GADOVIST®–enhanced MRA in the diagnosis of clinically significant abdominal or limb arterial diseases
    Medical condition: Patient suffering from Peripheral Arterial Occlusive Disease (PAOD) stage II or III
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062585 Peripheral arterial occlusive disease LLT
    9.1 10062585 Peripheral arterial occlusive disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003669-24 Sponsor Protocol Number: E-010-08-09 Start Date*: 2008-12-03
    Sponsor Name:Deutsches Krebsforschungszentrum
    Full Title: Intra-individual cross-over comparison of MultiHance® and Vasovist® enhanced MRA of the Carotids
    Medical condition: Patients with at least one stenosis of one carotid artery of at least 90% as confirmed by Doppler ultrasound or other radiological methods who are scheduled for i.a. DSA for clinical reasons (or wh...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007687 Carotid artery stenosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003662-14 Sponsor Protocol Number: GN17CA082 Start Date*: 2019-05-13
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Patiromer-facilitated, dose-escalation of mineralocorticoid antagonists for the management of worsening congestion in people with heart failure and hyperkalaemia. A Phase IV, registry-based, rand...
    Medical condition: People with heart failure, worsening symptoms and signs of congestion and serum potassium >5mmol/L
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 08:49:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA